Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38654078 | 0.80 | GAA (0.39) | KMT2AMEN1NPSR1SMN1; SMN2RAB9A | |
| SCHEMBL19948679 | 0.77 | SIGMAR1 (0.40) | KMT2AMEN1NPSR1SMN1; SMN2TSHR | |
| SCHEMBL31122973 | 0.76 | CTSK (0.35) | KMT2AMEN1NPSR1SMN1; SMN2SMYD2 | |
| SCHEMBL16351364 | 0.70 | ALDH1A1 (0.43) | KMT2AMEN1HTTSMN1; SMN2SMYD2 | |
| SCHEMBL31299431 | 0.69 | SMYD2 (0.38) | HTTSMN1; SMN2SMYD2 | |
| SCHEMBL1280597 | 0.69 | USP2 (0.63) | SMN1; SMN2RAB9AKDM4ETSHR | |
| SCHEMBL28606626 | 0.69 | KDM4E (0.36) | KMT2AMEN1HTTSMN1; SMN2SMYD2 | |
| SCHEMBL31299244 | 0.69 | NAMPT (0.37) | SMN1; SMN2SMYD2KDM4EPKM | |
| SCHEMBL29080145 | 0.69 | SMN1; SMN2 (0.40) | KMT2AMEN1NPSR1HTTSMN1; SMN2 | |
| SCHEMBL29680617 | 0.69 | NAMPT (0.37) | SMN1; SMN2SMYD2KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20230072276-A1 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072276-A1 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | KMT2A 586/4885MEN1 244/4885NPSR1 4225/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | KMT2A 586/4885MEN1 244/4885NPSR1 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.